3
Clinical Trials associated with HS-10342A Single-arm, Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of HS-10342 in Previously Treated Patients With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Advanced and/or Metastatic Breast Cancer
HS-10342 is a selective CDK4/6 kinase inhibitor. This study is conducted to evaluate the safety and efficacy of HS-10342 at repeated doses.
[Translation] Study on the effect of food on the pharmacokinetics of HS-10342
主要目的:评价在健康受试者中食物对HS-10342及其代谢产物HAS-002137药代动力学的影响。
次要目的:评价健康受试者单次口服HS-10342片后的安全性和耐受性。
[Translation] Primary objective: To evaluate the effect of food on the pharmacokinetics of HS-10342 and its metabolite HAS-002137 in healthy subjects.
Secondary objective: To evaluate the safety and tolerability of a single oral dose of HS-10342 tablets in healthy subjects.
A Phase 1, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10342 in Patients With Advanced Solid Tumor
HS-10342 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of HS-10342 in Chinese advanced solid tumor patients. Preliminary efficacy will be also investigated in this study.
100 Clinical Results associated with HS-10342
100 Translational Medicine associated with HS-10342
100 Patents (Medical) associated with HS-10342
100 Deals associated with HS-10342